|本期目录/Table of Contents|

[1]武传强,周 旋 综 述,张 仑 审 校.癌症免疫治疗相关的PD1-PDL1通路作用机制及其研究进展[J].天津医科大学学报,2019,25(03):300-304.
点击复制

癌症免疫治疗相关的PD1-PDL1通路作用机制及其研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25卷
期数:
2019年03期
页码:
300-304
栏目:
综述
出版日期:
2019-05-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2019)03-0300-05
作者:
武传强; 周 旋 综 述; 张 仑 审 校
（天津医科大学肿瘤医院颌面耳鼻喉头颈肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060）
Author(s):
-
关键词:
程序性凋亡蛋白1; 程序性凋亡蛋白1 配体; 肿瘤微环境; 变异负荷
Keywords:
-
分类号:
R730
DOI:
-
文献标志码:
A
摘要:
PD1-PDL1免疫检查点通路阻滞在癌症患者中引发了持久客观的反应，是一种非常有前景的治疗方法，然而部分患者对抗PD1治疗缺乏阳性反应，如何才能合理地应用免疫检查点阻断剂，成为一个亟待解决的问题。本文将从免疫学、基因学、病毒学角度讨论抗PD1治疗生物标志物，以促进免疫检查点阻滞联合治疗方案的优化，指导抗PD1药物的临床应用。
Abstract:
-

参考文献/References:

[1] Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252
[2] Pardoll D. Cancer and the immune system: basic concepts and targets for intervention[J]. Semin Oncol, 2015, 42(4): 523
[3] Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med, 2013, 369(2): 134
[4] Garon E B, Rizvi N A, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018
[5] Motzer R J, Rini B I, McDermott D F, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II Trial[J]. J Clin Oncol, 2015, 33(13): 1430
[6] Topalian S L, Hodi F S, Brahmer J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443
[7] Tumeh P C, Harview C L, Yearley J H, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568
[8] Kondou R, Iizuka A, Nonomura C, et al. Classification of tumor microenvironment immune types based on immune response-associated gene expression[J]. Int J Oncol, 2019, 54(1): 219
[9] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795):1960
[10] Fridman W H, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nat Rev Cancer, 2012, 12(4): 298
[11] George S, Miao D, Demetri G D, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma[J]. Immunity, 2017, 46(2): 197
[12] Ansell S M, Lesokhin A M, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J]. N Engl J Med, 2015, 372(4): 311
[13] Taube J M, Anders R A, Young G D, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J]. Sci Transl Med, 2012, 4(127):127
[14] Velcheti V, Schalper K A, Carvajal D E, et al. Programmed death ligand-1 expression in non-small cell lung cancer[J]. Lab Invest, 2014, 94(1):107
[15] Lyford-Pike S, Peng S, Young G D, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma[J]. Cancer Res, 2013, 73(6):1733
[16] Dong Z Y, Zhong W Z, Zhang X C, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(12): 3012
[17] Rodi N, Anders R A, Eshleman J R, et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation[J]. Cancer Immunol Res, 2015, 3(2):110
[18] Llosa N J, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J]. Cancer Discov, 2015, 5(1):43
[19] Cimino-Mathews A, Thompson E, Taube J M, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas[J]. Hum Pathol, 2016, 47(1): 52
[20] Thompson E D, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma[J]. Gut, 2017, 66(5):794
[21] Lipson E J, Forde P M, Hammers H J, et al. Antagonists of PD-1 and PD-L1 in Cancer Treatment[J]. Semin Oncol, 2015, 42(4): 587
[22] Sunshine J, Taube J M. PD-1/PD-L1 inhibitors[J]. Curr Opin Pharmacol, 2015, 23: 32
[23] Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells[J]. J Exp Med, 2006, 203(7):1651
[24] Clavé S, Pijuan L, Casadevall D, et al. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients[J]. Histopathology, 2018, 72(2): 259
[25] Larkin J, Lao C D, Urba W J, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials[J]. JAMA Oncol, 2015, 1(4): 433
[26] Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124
[27] Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma[J]. N Engl J Med, 2014, 371(23): 2189
[28] Twyman-Saint V C, Rech A J, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547): 373
[29] Gubin M M, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J]. Nature, 2014, 515(7528): 577
[30] Coulie P G, van den Eynde B J, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy[J]. Nat Rev Cancer, 2014, 14(2): 135
[31] Drescher K M, Sharma P, Watson P, et al. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer[J]. Fam Cancer, 2009, 8(3): 231
[32] Vétizou M, Pitt J M, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350(6264):1079
[33] Le D T, Uram J N, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509
[34] Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents[J]. Cancer Cell, 2015, 28(6): 690
[35] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1):23
[36] Ho P C, Bihuniak J D, Macintyre A N, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses[J]. Cell, 2015, 162(6):1217
[37] Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science, 2015, 350(6264):1084

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目（81572492,81872495,81872206）
作者简介 武传强（1992-），男，硕士在读，研究方向：头颈部肿瘤；
通信作者：张仑，E-mail：zhanglunsubmission@163.com。
更新日期/Last Update: 2019-07-03